Biomodels, a preclinical CRO, conducts predictive and translational studies for biotechnology and pharmaceutical companies in the areas of inflammatory and autoimmune diseases, fibrosis, pulmonary disease and cancer/cancer supportive care, in addition to several other clinical indications. Biomodels specializes in (non-GLP) efficacy studies that optimize dose, schedule, and define mechanism of action. Additionally, Biomodels’ state of the art Germ-Free and Gnotobiotic animal facility allows for the analysis of the role of the microbiota both in disease pathogenesis and in therapeutic efficacy.